Discussion {#s2}
==========

Therapeutic options for advanced low-grade NET are limited. First-line therapy involves a somatostatin analog, such as octreotide long-acting repeatable. Biologic therapies targeting mTOR pathway and vascular endothelial growth factor have been approved for the treatment of patients with well-differentiated pancreatic NET: sunitinib and everolimus, respectively. Both agents demonstrated the benefit of prolongation of PFS.

Panobinostat is a potent, orally active, pan-HDAC inhibitor that can affect multiple cancer-related pathways, including cell-cycle regulation, differentiation, and apoptosis. Several preclinical studies indicated that HDAC inhibitors, valproic acid and suberoyl bishydroxamic acid, can activate Notch1 signaling, suppress NET tumor markers, and inhibit NET cell growth. Based on the evidence that Notch1 activation can lead to NET differentiation and suppression of tumor growth, we opened a phase II clinical trial of panobinostat in patients with metastatic low-grade NETs.

The total number of subjects initially planned in this study was 33. An interim analysis was planned when 13 evaluable patients had been accrued. All patients had stable disease as best response ([Fig. 1](#F1){ref-type="fig"}). Because of lack of objective response, the study was closed to accrual. The median progression-free survival was 9.9 months (90% confidence interval \[CI\], 4.1--16.9), and the median overall survival was 47.27 months (90% CI, 17.87 to not reached), with the total follow-up time of 5 years. Panobinostat was tolerated relatively well in patients in our study. Fatigue, thrombocytopenia, anorexia, diarrhea, and nausea were the most common grade 3 treatment related toxicities (Adverse Events Table). Patients with pancreatic NETs (4 of 5 patients, 80%) underwent more than 10 cycles of panobinostat in this study. This would seem to be a clinically meaningful delay in time to progression of the cancer. It is increasingly clear that pancreatic NETs and carcinoid subtypes have different biology, respond differently to therapeutic agents, and should be evaluated as separate entities in clinical trials.

![Kaplan-Meier curve for median progression-free survival, which is 9.90 months with 90% confidence interval (4.10--16.9 months).](theoncologist_1660CTR_f1){#F1}

Our study was terminated early because of the use of objective response rate as the primary outcome measure, which is the shortcoming of this study. We would use progression-free survival (PFS) as the primary endpoint if the study should be repeated. Overall survival is not a practical endpoint for advanced NET studies.

Panobinostat showed favorable clinical activity in different hematologic malignancies, such as in relapsed Hodgkin lymphoma, myelofibrosis, refractory cutaneous T-cell lymphoma, and multiple myeloma, as either single-agent or combination treatment. However, HDAC inhibitors have not demonstrated effectiveness in clinical trials involving solid tumors. Their limitations in solid tumors could be related to drug instability because of short protein kinase half-life, tissue impermeability in tumor microenvironment, drug resistance due to activation of signal transducers and activators of transcription signaling pathway, antiapoptotic effect of nuclear transcription nuclear factor κB, and lack of the specific target in solid tumors. The question regarding the role of Notch1 in well-differentiated NET remains unanswered.

Trial Information {#s3}
=================

DiseaseNeuroendocrine -- pancreaticDiseaseNeuroendocrine -- otherStage of disease / treatmentMetastatic / AdvancedPrior TherapyNo designated number of regimensType of study - 1Phase IIType of study - 2Single ArmPrimary EndpointOverall Response RateSecondary EndpointProgression-Free SurvivalSecondary EndpointOverall SurvivalSecondary EndpointToxicitySecondary EndpointTolerabilityAdditional Details of Endpoints or Study DesignThe primary endpoint was the tumor response rate (complete or partial response) using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. A Simon optimal two-stage design was used to test the null hypothesis that the true response rate was 6% versus the alternative hypothesis that it was 20%. With a significance level of 10% and a power of 85%, at least one response was required among the first 13 evaluable patients to proceed to the second stage, where additional patients would be enrolled for a total of 30 evaluable patients.Investigator\'s AnalysisLevel of activity did not meet planned clinical trial endpoint.

Drug Information {#s4}
================

Drug 1Generic/Working namePanobinostatTrade nameFarydakCompany nameNovartisDrug typeSmall moleculeDrug classHDACDose20 mg per flat doseRouteOral (po)Schedule of AdministrationOnce daily, three times per week

Patient Characteristics {#s5}
=======================

Number of patients, male10Number of patients, female5StageMetastatic low-grade neuroendocrine tumorsAgeMedian (range): 57 (40--80)Number of prior systemic therapiesMedian (range): Not collectedPerformance Status: ECOG0 --- 101 --- 52 --- 03 --- 0Unknown ---Primary Site:Lung and bronchus, 2Pancreas, 5Rectum, 1Small Intestine, 5Unknown, 2Cancer Types or Histologic SubtypesLow,\* 6Well Differentiated,\* 5Grade unknown, not stated, or not applicable, 4

Primary Assessment Method {#s6}
=========================

Control Arm: Total Patient PopulationNumber of patients screened15Number of patients enrolled15Number of patients evaluable for toxicity15Number of patients evaluated for efficacy13Response assessment CR*n* = 0Response assessment PR*n* = 0Response assessment SD*n* = 13Response assessment PD*n* = 0(Median) duration assessments PFS9.9 months, CI: 90(Median) duration assessments OS47.3 monthsKaplan-Meier time unitsMonths

Adverse Events {#s7}
==============

Assessment, Analysis, and Discussion {#s8}
====================================

CompletionStudy completedTerminated reasonDid not fully accruePharmacokinetics / PharmacodynamicsNot CollectedInvestigator\'s AssessmentLevel of activity did not meet planned clinical trial endpoint

NETs are uncommon tumors arising from the neuroendocrine system. The gastrointestinal (GI) tract, pancreas, and lung are the most common primary tumor sites in patients with NETs \[[@B1]\], and gastroenteropancreatic (GEP) NETs represent approximately 2% of all gastrointestinal malignant neoplasms. The clinical evaluation for NETs should incorporate several key factors, such as anatomic site, histology, grade, differentiation, and hormone secretion. In particular, the anatomic site of origin is now recognized as a key determinant of treatment selection \[[@B2]\]. According to the 2010 World Health Organization grading system for GEP NETs, there are three grades (G1, G2, and G3) for differentiation on pathology report, based on Ki-67 and mitotic counts \[[@B3]\]. Well-differentiated NETs include G1 and G2; poorly differentiated NETs are G3.

For patients with well-differentiated and functional tumors, somatostatin analogs such as octreotide long-acting repeatable are the mainstay of treatment for control tumor growth as well as symptomatic control, with improved PFS and quality of life \[[@B4], [@B5]\]. Recent randomized studies for biologic therapies targeting mTOR pathway and vascular endothelial growth factor demonstrated prolongation of PFS compared with placebo for pancreatic NET; for example, everolimus (11 vs. 4.6 months) \[[@B6]\] or sunitinib (11.4 vs. 5.5 months) \[[@B7]\].

Early studies suggested that activation of the Notch pathway can lead to neuroendocrine differentiation in gastrointestinal carcinoid tumor \[[@B8]\] and inhibit NET cell growth \[[@B9]\]. Of note, it is well recognized that Notch can function as either an oncogene or a tumor suppressor, depending on the cell type \[[@B10]--[@B12]\]. Both valproic acid (VPA) and suberoyl bishydroxamic acid, two histone deacetylase (HDAC) inhibitors, can activate Notch1 signaling, suppress neuroendocrine tumor markers, and inhibit NET cell growth both in vitro and in vivo \[[@B13], [@B14]\]. Furthermore, our group previously conducted a pilot clinical trial of VPA for patients with advanced carcinoid cancer. Five of the six patients (62.5%) assessable for radiographic response were noted to have stable disease by RECIST, and one patient with an unconfirmed partial response was noted to have a 40-fold increase in Notch1 mRNA levels \[[@B15]\].

Panobinostat (LBH589) is a potent, orally active, pan-HDAC inhibitor that can affect multiple cancer-related pathways via nonhistone protein targets, including cell-cycle regulation, differentiation, and apoptosis \[[@B16], [@B17]\]. Based on the role of Notch1 activation in suppression of NET tumor markers and tumor growth, we opened a phase II clinical trial of HDAC inhibitor panobinostat in patients with metastatic low-grade NETs.

The total number of subjects initially planned for this study was 33. An interim analysis was planned when 13 evaluable patients had been accrued. At least one response was required among the first 13 evaluable patients to proceed to the second stage, where additional patients would be enrolled. Among 15 patients who were accrued, 66.6% were male, age range 40--80 years old, 54% carcinoid, and 33% pancreatic NET ([Table 1](#T1){ref-type="table"}). Because of the lack of objective response in the interim analysis, the study was closed. Panobinostat was tolerated relatively well in patients in our study. The most common toxicities of all grades were thrombocytopenia, fatigue, diarrhea, nausea, hyperglycemia, hypertriglyceridemia, and thyroid dysfunction. Fatigue (27%), thrombocytopenia (20%), anorexia (20%), diarrhea (13%), and nausea (13%) were the most common treatment-related grade 3 toxicities. There was one case (7%) of grade 4 toxicity of thrombocytopenia (Adverse Events Table). Eight patients needed dose modifications because of adverse events, such as thrombocytopenia, neutropenia, and fatigue, during their treatment courses (data not shown). All patients had stable disease as best response ([Fig. 1](#F1){ref-type="fig"}). Three of 13 patients underwent only 2 cycles of treatment, whereas 7 patients underwent more than 10 cycles of treatment ([Table 2](#T2){ref-type="table"}). Median progression-free survival was 9.9 months (90% CI, 4.1--16.9) ([Fig. 2](#F2){ref-type="fig"}), and median overall survival was 47.27 months (90% CI, 17.87 to not reached), with the total follow-up time of 5 years ([Fig. 3](#F3){ref-type="fig"}).

###### 

Patient characteristics
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###### 

Patient tumor characteristics and treatment outcome
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![Percentage change in tumor size based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Waterfall plot of radiographic changes from baseline to best response of 13 evaluable patients, revealing that every patient (100%) has stable disease. Stable disease is defined as neither sufficient shrinkage to qualify for partial response (less than 30% decrease in the sum of the longest diameters of target lesions) nor sufficient increase to qualify for progressive disease (at least 20% increase in the sum of the longest diameters of target lesions).](theoncologist_1660CTR_f2){#F2}

![Kaplan-Meier curve for overall survival, which is 47.27 months with 90% confidence interval, with a follow-up time of 5 years.\
Abbreviation: CI, confidence interval.](theoncologist_1660CTR_f3){#F3}

![Kaplan-Meier curve for median progression-free survival, which is 9.90 months with 90% confidence interval (4.10--16.9 months).](theoncologist_1660CTR_f4){#F4}

Patients with pancreatic NETs (four of five patients; one patient withdrew early) underwent more than 10 cycles of panobinostat in this study, although our sample size is too small to draw any conclusion. It is increasingly clear that pancreatic NETs (PNETs) and carcinoid subtypes have different biology, respond differently to therapeutic agents, and should be evaluated as separate entities in clinical trials \[[@B18]\]. Examination of the PNETs and GI carcinoid demonstrated only a few areas of overlap in the accumulation of genetic aberrations, using comparative genomic hybridization, microsatellite analysis, and sequencing techniques \[[@B19]\]. As to treatment, PNETs are more sensitive to cytotoxic chemotherapy than carcinoid tumors, such as streptozocin, capecitabine, and temozolomide, as shown in early clinical trials as well as recent retrospective clinical studies \[[@B20]--[@B22]\].

Our study was terminated early because of the use of objective response rate as the primary outcome measure, which is the shortcoming of this study. We would use progression-free survival as the primary endpoint if the study should be repeated. The challenge in phase II studies in NETs is the small patient population available and the often long survival postprogression \[[@B23]\]. Overall survival is not a practical endpoint for advanced NET studies, because of the nature of indolent disease and the availability of multiple sequential therapies \[[@B2]\].

Panobinostat showed favorable clinical activity in different hematologic malignancies, such as in relapsed Hodgkin lymphoma \[[@B24]\], myelofibrosis \[[@B25]\], refractory cutaneous T-cell lymphoma \[[@B26]\], and multiple myeloma \[[@B27]\], as either single-agent or combination treatment. However, the results of recent clinical trials of panobinostat in solid tumors are disappointing, including castration-resistant prostate cancer \[[@B28]\], metastatic renal cell cancer \[[@B29]\], and pancreatic cancer \[[@B30]\]. Generally, HDAC inhibitors have not demonstrated effectiveness in clinical trials involving solid tumors. Their limitations in solid tumors could be related to drug instability due to short protein kinase half-life \[[@B31], [@B32]\], tissue impermeability in tumor microenvironment, drug resistance due to activation of the signal transducers and activators of transcription signaling pathway \[[@B33], [@B34]\], antiapoptotic effect of nuclear transcription nuclear factor κB \[[@B35]\], and lack of the specific target in solid tumors \[[@B36]\]. There was no study participant in our trial who underwent pretreatment and posttreatment biopsy for Notch1 activity, which is the limitation of this study.

In conclusion, panobinostat has a high stable disease rate and reasonable PFS in low-grade NET. Oral panobinostat at a dose of 20 mg three times weekly was relatively well tolerated in patients in this study. Four of five patients with PNETs had durable stable disease on panobinostat, which is encouraging. Further studies of panobinostat in combination with other agents are indicated in patients with NETs. The questions regarding off-target effects of panobinostat and the role of Notch1 in well-differentiated NET remain unanswered. In future clinical trials, it is important to develop pharmacodynamics biomarkers to predict treatment response in patients.
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